<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, April 3, 2019 (HealthDay News) — In women at high risk for late preterm delivery, antenatal treatment with betamethasone is a cost-effective strategy, according to a study published online March 11 in JAMA Pediatrics<\/i>.<\/p>\n
Cynthia Gyamfi-Bannerman, M.D., from the Columbia University Medical Center in New York City, and colleagues used data from the Antenatal Late Preterm Steroids trial to compare the cost-effectiveness of treatment with antenatal corticosteroids to no treatment for women at risk for late preterm delivery. Participants included 1,426 mother-infant pairs in the betamethasone group and 1,395 mother-infant pairs in the placebo group.<\/p>\n
The researchers found that treatment with betamethasone was associated with a total mean woman-infant pair cost of $4,681, which was significantly less than the mean cost of $5,379 for woman-infant pairs in the placebo group. The trial previously demonstrated that betamethasone use is effective with respect to decreased respiratory morbidity (a 2.9 percent decrease), yielding an incremental cost-effectiveness ratio of \u221223,986.<\/p>\n
“Because late preterm birth comprises a large proportion of all preterm births, our findings have the potential for a large influence on public health,” the authors write.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n